Details:
Under the collaboration, the Company will produce a prototype drug utilising Poolbeg's licensed oral delivery technology. Poolbeg believes that this technology can help to optimise the delivery of its partner's novel drug to its ideal site of therapeutic action.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 17, 2023
Details:
These precisely reprogrammed cell types are generated with the company’s precision cellular reprogramming technology opti-oxTM that enables unlimited batches of any human cell to be manufactured consistently at scale.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2022
Details:
First neurodegenerative disease model launched from bit.bio's new ioDisease Model portfolio. Accurately replicates Huntington's disease genotype in human cells, setting a new standard in cell models for drug discovery.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
Proceeds from the financing will be used to advance OMass’s portfolio towards clinical trials. This includes the development of an insurmountable antagonist of the MC2 receptor for congenital adrenal hyperplasia.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: GV
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 28, 2022
Details:
The financing will enable LoQus23 to identify a small molecule drug candidate for the company's lead MMR target and explore other MMR proteins for their role in somatic instability in TRDs.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Dementia Discovery Fund
Deal Size: $9.4 million Upfront Cash: Undisclosed
Deal Type: Financing November 23, 2021
Details:
Company introduces MC2 (melanocortin-2), a GPCR that binds to ACTH, aiming to develop an insurmountable antagonist with a best-in-class profile for rare endocrine disorders, including, Congenital Adrenal Hyperplasia and Cushing’s Disease.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2021